The company is currently developing three proprietary therapeutics with unique mechanisms of action, including an oral antitumoral agent that crosses the blood-brain barrier, an IV antitumoral agent with high selectivity towards cancer cells, and an antibody drug conjugate. Diaccurate has formed partnerships with prestigious institutions and industry leaders, such as the Pasteur Institute and Merck KGaA. It is led by a high-level management team and a Scientific Advisory Board chaired by Prof. Tasuku Honjo, a Nobel Prize recipient.